CI 1002

Drug Profile

CI 1002

Alternative Names: PD 142676

Latest Information Update: 27 Oct 1999

Price : $50

At a glance

  • Originator Pfizer
  • Class Neuroprotectants; Nootropics; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Alzheimer's disease

Most Recent Events

  • 27 Oct 1999 Discontinued-I for Alzheimer's disease in USA (PO)
  • 21 Jul 1999 No-Development-Reported for Alzheimer's disease in USA (PO)
  • 10 Mar 1997 Phase-I clinical trials for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top